Investigating the effects of a hydrolytically stable hapten and a Th1 adjuvant on heroin vaccine performance

Journal of Medicinal Chemistry

Volumn 55, Issue 23, 2012, Pages 10776-10780

  Bremer, Paul T ^a   Janda, Kim D ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 ACETAMIDE DERIVATIVE; ACETAMIDE DERIVATIVE; ALUMINUM POTASSIUM SULFATE; CPG OLIGODEOXYNUCLEOTIDE; HAPTEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DEACETYLATION; DRUG DESIGN; DRUG FORMULATION; DRUG HALF LIFE; DRUG STABILITY; FEMALE; HEROIN DEPENDENCE; HUMORAL IMMUNITY; HYDROLYSIS; MOUSE; NONHUMAN; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ANTIBODY FORMATION; HAPTENS; HEROIN; HUMANS; HYDROLYSIS; TH1 CELLS; VACCINES;

EID: 84871031431     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301262z     Document Type: Article

References (41)

1. Degenhardt, L.; Hall, W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease Lancet 2012, 379 (9810) 55-70
2. Garten, R. J.; Lai, S.; Zhang, J.; Liu, W.; Chen, J.; Vlahov, D.; Yu, X. F. Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China Int. J. Epidemiol. 2004, 33 (1) 182-188
3. Hien, N. T.; Giang, L. T.; Binh, P. N.; Deville, W.; van Ameijden, E. J.; Wolffers, I. Risk factors of HIV infection and needle sharing among injecting drug users in Ho Chi Minh City, Vietnam J. Subst. Abuse 2001, 13 (1-2) 45-58
4. Samuel, M. C.; Doherty, P. M.; Bulterys, M.; Jenison, S. A. Association between heroin use, needle sharing and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA Epidemiol. Infect. 2001, 127 (3) 475-84
5. Nutt, D. J.; King, L. A.; Phillips, L. D. Drug harms in the UK: a multicriteria decision analysis Lancet 2010, 376 (9752) 1558-1565
6. Benyamin, R.; Trescot, A. M.; Datta, S.; Buenaventura, R.; Adlaka, R.; Sehgal, N.; Glaser, S. E.; Vallejo, R. Opioid complications and side effects Pain Physician 2008, 11 (Suppl 2) S105-S120
7. van Dorp, E. L.; Yassen, A.; Dahan, A. Naloxone treatment in opioid addiction: the risks and benefits Expert Opin. Drug Saf. 2007, 6 (2) 125-132
8. Maxwell, S.; Shinderman, M. S. Optimizing long-term response to methadone maintenance treatment: a 152-week follow-up using higher-dose methadone J. Addictive Dis. 2002, 21 (3) 1-12
9. Mark, T. L.; Woody, G. E.; Juday, T.; Kleber, H. D. The economic costs of heroin addiction in the United States Drug Alcohol Depend. 2001, 61 (2) 195-206
10. Dekimpe, M. G.; Gucht, L. M. V. D.; Hanssens, D. M.; Powers, K. I. Long-Run Abstinence after Narcotics Abuse: What Are the Odds? Manage. Sci. 1998, 44 (11) 1478-1492
11. Gossop, M.; Stewart, D.; Browne, N.; Marsden, J. Factors associated with abstinence, lapse or relapse to heroin use after residential treatment: protective effect of coping responses Addiction 2002, 97 (10) 1259-1267
12. Kosten, T. R.; Rosen, M.; Bond, J.; Settles, M.; Roberts, J. S. C.; Shields, J.; Jack, L.; Fox, B. Human therapeutic cocaine vaccine: safety and immunogenicity Vaccine 2002, 20 (7-8) 1196-1204
13. Martell, B. A.; Mitchell, E.; Poling, J.; Gonsai, K.; Kosten, T. R. Vaccine Pharmacotherapy for the Treatment of Cocaine Dependence Biol. Psychiatry 2005, 58 (2) 158-164
14. Stowe, G. N.; Vendruscolo, L. F.; Edwards, S.; Schlosburg, J. E.; Misra, K. K.; Schulteis, G.; Mayorov, A. V.; Zakhari, J. S.; Koob, G. F.; Janda, K. D. A vaccine strategy that induces protevtice immunity against heroin J. Med. Chem. 2011, 54, 5195-5204
15. Carrera, M. R.; Ashley, J. A.; Wirsching, P.; Koob, G. F.; Janda, K. D. A second-generation vaccine protects against the psychoactive effects of cocaine Proc. Natl. Acad. Sci. U. S. A. 2001, 98 (4) 1988-1992
16. Barrett, D. A.; Dyssegaard, A. L.; Shaw, P. N. The effect of temperature and pH on the deacetylation of diamorphine in aqueous solution and in human plasma J. Pharm. Pharmacol. 1992, 44 (7) 606-608
17. Verthelyi, D.; Ishii, K. J.; Gursel, M.; Takeshita, F.; Klinman, D. M. Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs J. Immunol. 2001, 166 (4) 2372-2377
18. Krug, A.; Rothenfusser, S.; Hornung, V.; Jahrsdorfer, B.; Blackwell, S.; Ballas, Z. K.; Endres, S.; Krieg, A. M.; Hartmann, G. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells Eur. J. Immunol. 2001, 31 (7) 2154-2163
19. Hartmann, G.; Krieg, A. M. Mechanism and function of a newly identified CpG DNA motif in human primary B cells J. Immunol. 2000, 164 (2) 944-953
20. Brazolot Millan, C. L.; Weeratna, R.; Krieg, A. M.; Siegrist, C. A.; Davis, H. L. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice Proc. Natl. Acad. Sci. U. S. A. 1998, 95 (26) 15553-15558
21. Weeratna, R.; Comanita, L.; Davis, H. L. CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB//c mice Immunol. Cell Biol. 2003, 81 (1) 59-62
22. Zakhartchouk, A. N.; Sharon, C.; Satkunarajah, M.; Auperin, T.; Viswanathan, S.; Mutwiri, G.; Petric, M.; See, R. H.; Brunham, R. C.; Finlay, B. B.; Cameron, C.; Kelvin, D. J.; Cochrane, A.; Rini, J. M.; Babiuk, L. A. Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine Vaccine 2007, 25 (1) 136-143
23. Vajdy, M.; Selby, M.; Medina-Selby, A.; Coit, D.; Hall, J.; Tandeske, L.; Chien, D.; Hu, C.; Rosa, D.; Singh, M.; Kazzaz, J.; Nguyen, S.; Coates, S.; Ng, P.; Abrignani, S.; Lin, Y. L.; Houghton, M.; O'Hagan, D. T. Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses J. Gen. Virol. 2006, 87 (Pt 8) 2253-2262
24. Wentland, M. P.; Duan, W.; Cohen, D. J.; Bidlack, J. M. Selective protection and functionalization of morphine: synthesis and opioid receptor binding properties of 3-amino-3-desoxymorphine derivatives J. Med. Chem. 2000, 43 (19) 3558-3565
25. Corey, E. J.; Cho, H.; Rucker, C.; Hua, D. H. Studies with Trialkylsilyltriflates-New Syntheses and Applications Tetrahedron Lett. 1981, 22 (36) 3455-3458
26. Wolfe, J P.; Åhman, J.; Sadighi, J. P.; Singer, R. A.; Buchwald, S. L. An Ammonia Equivalent for the Palladium-Catalyzed Amination of Aryl Halides and Triflates Tetrahedron Lett. 1997, 38 (36) 6367-6370
27. Oriyama, T.; Oda, M.; Gono, J.; Koga, G. A One-Step and Chemoselective Conversion of Silyl-Protected Alcohols into the Corresponding Acetates Tetrahedron Lett. 1994, 35 (13) 2027-2030
28. Waibler, Z.; Anzaghe, M.; Konur, A.; Akira, S.; Muller, W.; Kalinke, U. Excessive CpG 1668 stimulation triggers IL-10 production by cDC that inhibits IFN-alpha responses by pDC Eur. J. Immunol. 2008, 38 (11) 3127-3137
29. Tudor, D.; Yu, H.; Maupetit, J.; Drillet, A. S.; Bouceba, T.; Schwartz-Cornil, I.; Lopalco, L.; Tuffery, P.; Bomsel, M. Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody Proc. Natl. Acad. Sci. U. S. A. 2012, 109 (31) 12680-12685
30. McLean, G. R.; Torres, M.; Elguezabal, N.; Nakouzi, A.; Casadevall, A. Isotype can affect the fine specificity of an antibody for a polysaccharide antigen J. Immunol. 2002, 169 (3) 1379-1386
31. Cooper, L. J.; Shikhman, A. R.; Glass, D. D.; Kangisser, D.; Cunningham, M. W.; Greenspan, N. S. Role of heavy chain constant domains in antibody-antigen interaction. Apparent specificity differences among streptococcal IgG antibodies expressing identical variable domains J. Immunol. 1993, 150 (6) 2231-2242
32. Casadevall, A.; Janda, A. Immunoglobulin isotype influences affinity and specificity Proc. Natl. Acad. Sci. U. S. A. 2012, 109 (31) 12272-12273
33. Hosokawa, M.; Furihata, T.; Yaginuma, Y.; Yamamoto, N.; Koyano, N.; Fujii, A.; Nagahara, Y.; Satoh, T.; Chiba, K. Genomic structure and transcriptional regulation of the rat, mouse, and human carboxylesterase genes Drug Metab. Rev. 2007, 39 (1) 1-15
34. Satoh, T.; Hosokawa, M. The mammalian carboxylesterases: from molecules to functions Annu. Rev. Pharmacol. Toxicol. 1998, 38, 257-288
35. Oldendorf, W. H.; Hyman, S.; Braun, L.; Oldendorf, S. Z. Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection Science 1972, 178 (4064) 984-986
36. Andersen, J. M.; Ripel, A.; Boix, F.; Normann, P. T.; Morland, J. Increased locomotor activity induced by heroin in mice: pharmacokinetic demonstration of heroin acting as a prodrug for the mediator 6-monoacetylmorphine in vivo J. Pharmacol. Exp. Ther. 2009, 331 (1) 153-161
37. Jiang, J. B.; Hanson, R. N.; Portoghese, P. S.; Takemori, A. E. Stereochemical studies on medicinal agents. 23. Synthesis and biological evaluation of 6-amino derivatives of naloxone and naltrexone J. Medi. Chem. 1977, 20 (8) 1100-1102
38. Fang, S.; Takemori, A. E.; Portoghese, P. S. Activities of morphinone and N -(cyclopropylmethyl)normorphinone at opioid receptors J. Med. Chem. 1984, 27 (10) 1361-1363
39. Uchida, K.; Yokoshima, S.; Kan, T.; Fukuyama, T. Total synthesis of (±)-morphine Org. Lett. 2006, 8 (23) 5311-5313
40. Majumdar, S.; Subrath, J.; Le Rouzic, V.; Polikar, L.; Burgman, M.; Nagakura, K.; Ocampo, J.; Haselton, N.; Pasternak, A. R.; Grinnell, S.; Pan, Y. X.; Pasternak, G. W. Synthesis and Evaluation of Aryl-Naloxamide Opiate Analgesics Targeting Truncated Exon 11-Associated mu Opioid Receptor (MOR-1) Splice Variants J. Med. Chem. 2012, 55 (14) 6352-6362
41. Chen, X.; Pravetoni, M.; Bhayana, B.; Pentel, P. R.; Wu, M. X. High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants. Vaccine 2012, epub ahead of print.